Skip to main content
SpringerLink
Log in

Urine-Based Assays Complementing Cytologic Examination in the Detection of Urothelial Neoplasm

  • Chapter
  • First Online:
Koss's Cytology of the Urinary Tract with Histopathologic Correlations

  • 973 Accesses

Abstract

In this article, five markers of bladder cancer approved by the US Food and Drug Administration (FDA), as well as ten other urine-based markers that have been shown to be clinically useful, all of which could be substitutes of cystoscopy and/or cytology. Immunocytochemical detection of markers in exfoliated urothelial cells is separately reviewed. Comparison of urine markers and cytology as to the sensitivity, specificity, and cost is also discussed [1–3].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 109.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 139.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 139.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Lokeshwar VB, Schroeder GL, Selzer MG, et al. Bladder tumor markers for monitoring recurrence and screening comparison of hyaluronic acid-hyaluronidase and BTA-Stat tests. Cancer. 2002;95:61–72.

    Article  PubMed  Google Scholar 

  2. Vrooman OPJ, Witjes JA. Molecular markers for detection, surveillance and prognostication of bladder cancer. Int J Urol. 2009;16:234–43.

    Article  PubMed  CAS  Google Scholar 

  3. Lokeshwar VB, Habuchi T, Grossman HB, et al. Bladder tumor markers beyond cytology: international consensus panel on bladder tumor markers. Urology. 2005;66(Suppl 6A):35–63.

    Article  PubMed  Google Scholar 

  4. Grossman HB, Messing E, Soloway M, et al. Detection of bladder cancer using a point-of-care proteomic assay. JAMA. 2005;293:810–6.

    Article  PubMed  CAS  Google Scholar 

  5. Grossman HB, Soloway M, Messing E, et al. Surveillance for recurrent bladder cancer using a point-of-care proteomic assay. JAMA. 2006;295:299–305.

    Article  PubMed  CAS  Google Scholar 

  6. Topsakal M, Karadeniz T, Anaç M, Dönmezer S, Besisik A. Assessment of fibrin-fibrinogen degradation products (Accu-Dx) test in bladder cancer patients. Eur Urol. 2001;39:287–91.

    Article  PubMed  CAS  Google Scholar 

  7. Têtu B, Tiguert R, Harel F, Fradet Y. ImmunoCyt/uCyt  +  ™ improves the sensitivity of urine cytology in patients followed for urothelial carcinoma. Mod Pathol. 2005;18:83–9.

    Article  PubMed  Google Scholar 

  8. Mian C, Maier K, Comploj E, et al. uCyt+/ImmunoCyt™ in the detection of recurrent urothelial carcinoma: An update on 1991 analyses. Cancer. 2006;108:60–5.

    Article  PubMed  Google Scholar 

  9. Messing EM, Teot L, Korman H, et al. Performance of urine test in patients monitored for recurrence of bladder cancer: a multicenter study in the United States. J Urol. 2005;174:1238–41.

    Article  PubMed  Google Scholar 

  10. Placer J, Espinet B, Salido M, Solé F, Gelabert-Mas A. Clinical utility of a multiprobe FISH assay in voided urine specimens for the detection of bladder cancer and its recurrences, compared with urine cytology. Eur Urol. 2002;42:547–52.

    Article  PubMed  Google Scholar 

  11. Laudadio J, Keane TE, Reeves HM, Savage SJ, Hoda RS, Lage JM, Wolff DJ. Fluorescence in situ hybridization for detecting transitional cell carcinoma: implications for clinical practice. BJU Int. 2005;96:1280–5.

    Article  PubMed  Google Scholar 

  12. Moonen PM, Merkx GF, Peelen P, Karthaus HF, Smeets DF, Witjes JA. UroVysion compared with cytology and quantitative cytology in the surveillance of non-muscle-invasive bladder cancer. Eur Urol. 2007;51:1275–80.

    Article  PubMed  Google Scholar 

  13. Yoder BJ, Skacel M, Hedgepeth R, et al. Reflex UroVysion testing of bladder cancer surveillance patients with equivocal or negative urine cytology: a prospective study with focus on the natural history of anticipatory positive findings. Am J Clin Pathol. 2007;127:295–301.

    Article  PubMed  Google Scholar 

  14. Shariat SF, Ashfaq R, Karakiewicz PI, Saeedi O, Sagalowsky AI, Lotan Y. Survivin expression is associated with bladder cancer presence, stage, progression, and mortality. Cancer. 2007;109:1106–13.

    Article  PubMed  CAS  Google Scholar 

  15. Pu X-Y, Wang Z-P, Chen Y-R, Wang X-H, Wu Y-L, Wang H-P. The value of combined use of survivin, cytokeratin 20 and mucin 7 mRNA for bladder cancer detection in voided urine. J Cancer Res Clin Oncol. 2008;134:659–65.

    Article  PubMed  CAS  Google Scholar 

  16. May M, Hakenberg OW, Gunia S, et al. Comparative diagnostic value of urine cytology, UBC-ELISA, and fluorescence in situ hybridization for detection of transitional cell carcinoma of urinary bladder in routine clinical practice. Urology. 2007;70:449–53.

    Article  PubMed  Google Scholar 

  17. Bian W, Xu Z. Combined assay of CYFRA21-1, telomerase and vascular endothelial growth factor in the detection of bladder transitional cell carcinoma. Int J Urol. 2007;14:108–11.

    Article  PubMed  CAS  Google Scholar 

  18. Passerotti CC, Bonfim A, Martins JR, et al. Urinary hyaluronan as a marker for the presence of residual transitional cell carcinoma of the urinary bladder. Eur Urol. 2006;49:71–5.

    Article  PubMed  CAS  Google Scholar 

  19. Eissa S, Swellam M, Ali-Labib R, Mansour A, El-Malt O, Tash FM. Detection of telomerase in urine by 3 methods: evaluation of diagnostic accuracy for bladder cancer. J Urol. 2007;178:1668–72.

    Article  Google Scholar 

  20. Wiener HG, Mian C, Haitel A, Pycha A, Schatzl G, Marberger M. Can urine bound diagnostic tests replace cystoscopy in the management of bladder cancer? J Urol. 1998;159:1876–80.

    Article  PubMed  CAS  Google Scholar 

  21. Miyake M, Sugano K, Kawashima K, et al. Sensitive detection of FGFR3 mutations in bladder cancer and urine sediments by peptide nucleic acid-mediated real-time PCR clamping. Biochem Biophys Res Commun. 2007;362:865–71.

    Article  PubMed  CAS  Google Scholar 

  22. Zuiverloon TC, van der Aa MN, van der Kwast TH, et al. Fibroblast growth factor receptor 3 mutation analysis on voided urine for surveillance of patients with low-grade non-muscle-invasive bladder cancer. Clin Cancer Res. 2010;16:3011–8.

    Article  PubMed  CAS  Google Scholar 

  23. Eissa S, Salem AM, Zohny SF, Hegazy MGA. The diagnostic efficacy of urinary TGF-β1 and VEGF in bladder cancer: comparison with voided urine cytology. Cancer Biomark. 2007;3:275–85.

    PubMed  CAS  Google Scholar 

  24. Bhatia A, Dey P, Kumar Y, et al. Expression of cytokeratin 20 in urine cytology smears: a potential marker for the detection of urothelial carcinoma. Cytopathology. 2007;18:84–6.

    Article  PubMed  CAS  Google Scholar 

  25. Soyuer I, Sofikerim M, Tokat F, Soyuer S, Ozturk F. Which urine marker test provides more diagnostic value in conjunction with standard cytology-ImmunoCyt/uCyt+  or cytokeratin 20 expression. Diagn Pathol. 2009;4:20.

    Article  PubMed  Google Scholar 

  26. Righi E, Rossi G, Ferrari G, et al. Does p53 immunostaining improve diagnostic accuracy in urine cytology? Diagn Cytopathol. 1997;17:436–9.

    Article  PubMed  CAS  Google Scholar 

  27. Oğuztüzün S, Sezgin Y, Yazici S, Firat P, Özhavzali M, Özen H. Expression of glutathione-S-transferases isoenzymes and P53 in exfoliated human bladder cancer cells. Urol Oncol. 2011;29:538–44.

    Article  PubMed  Google Scholar 

  28. Menke TB, Boettcher K, Krüger S, et al. Ki-67 protein concentrations in urothelial bladder carcinomas are related to Ki-67-specific RNA concentrations in urine. Clin Chem. 2004;50:1461–3.

    Article  PubMed  CAS  Google Scholar 

  29. Nakazawa K, Murata S-i, Yuminamochi T. p16INK4a expression analysis as an ancillary tool for cytologic diagnosis of urothelial carcinoma. Am J Clin Pathol. 2009;132:776–84.

    Article  PubMed  Google Scholar 

  30. Politi EN, Lazaris AC, Lambropoulou S, Alexopoulou D, Kyriakidou V, Koutselini H. Epidermal growth factor receptor and proliferating cell nuclear antigen expression in urine ThinPrep specimens. Cytopathology. 2005;16:303–8.

    Article  PubMed  CAS  Google Scholar 

  31. Ross JS, Cheung C, Sheehan C, del Rosario AD, Bui HX, Fisher HA. E-cadherin cell-adhesion molecule expression as a diagnostic adjunct in urothelial cytology. Diagn Cytopathol. 1996;14:310–5.

    Article  PubMed  CAS  Google Scholar 

  32. Sawczuk IS, Pickens CL, Vasa UR, et al. DD23 biomarker: a prospective clinical assessment in routine urinary cytology specimens from patients being monitored for TCC. Urol Oncol. 2002;7:185–90.

    Article  PubMed  CAS  Google Scholar 

  33. van Rhijn BWG, van der Poel HG, van der Kwast TH. Urine markers for bladder cancer surveillance: a systematic review. Eur Urol. 2005;47:736–48.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University Emeritus Montefiore Medical Center Albert Einstein College of Medicine, Bronx, NY, USA

    Leopold G. Koss MD, Doct. HC (multiple) (Distinguished Professor)

  2. Department of Pathology and Laboratory Medicine, New York Presbyterian Hospital Weill Cornell Medical College, New York, NY, USA

    Rana S. Hoda MD, FIAC (Professor of Pathology and Director of Papanicolaou Cytology Laboratory)

Authors
  1. Leopold G. Koss MD, Doct. HC (multiple)
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rana S. Hoda MD, FIAC
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hiroshi Miyamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Leopold G. Koss

About this chapter

Cite this chapter

Koss, L.G., Hoda, R.S., Miyamoto, H. (2012). Urine-Based Assays Complementing Cytologic Examination in the Detection of Urothelial Neoplasm. In: Koss's Cytology of the Urinary Tract with Histopathologic Correlations. Springer, Boston, MA. https://doi.org/10.1007/978-1-4614-2056-9_7

Download citation

  • DOI: https://doi.org/10.1007/978-1-4614-2056-9_7

  • Published:

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4614-2055-2

  • Online ISBN: 978-1-4614-2056-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation